GB:0REN's free cash flow for Q4 2023 was $8.80M. For the 2023 fiscal year, GB:0REN's free cash flow was decreased by $-307.40M and operating cash flow was $110.40M. See a summary of the company’s cash flow.

Cash Flow	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Operating Cash Flow	$ 895.80M	$ 895.80M	$ 1.20B	$ 1.85B	$ 1.05B	$ 1.18B
Investing Cash Flow	$ 173.80M	$ 173.80M	$ 268.80M	$ -1.84B	$ -531.10M	$ -595.80M
Financing Cash Flow	$ -711.00M	$ -711.00M	$ -1.58B	$ -356.30M	$ -486.90M	$ -115.60M
Cash Flow From Discontinued Operation	-	-	-	-	-	-
Other Cash Adjustment Inside Changein Cash	-	-	-	-	-	-
End Cash Position	$ 4.48B	$ 1.15B	$ 772.60M	$ 867.40M	$ 1.20B	$ 1.18B
Income Tax Paid Supplemental Data	-	-	-	-	-	$ 61.50M
Interest Paid Supplemental Data	-	-	-	-	-	$ 19.90M
Issuance Of Capital Stock	$ 169.90M	$ 169.90M	$ 146.40M	$ 158.60M	-	$ 160.50M
Issuance Of Debt	$ -300.00K	$ -300.00K	$ -200.00K	$ -1.80M	$ 16.20M	$ 18.90M
Repayment Of Debt	$ -300.00K	$ -300.00K	$ -200.00K	$ -7.00M	$ -17.00M	$ -28.90M
Free Cash Flow	$ 629.50M	$ 629.50M	$ 936.90M	$ 1.52B	$ 647.00M	$ 904.50M
Domestic Sales	-	-	-	-	-	-
Foreign Sales	-	-	-	-	-	-

Currency in USD

Edwards Lifesciences Cash Flow

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing